Swedish Orphan Biovitrum has decided to move Kiobrina into phase III development
The combined results of the two clinical studies showed a statistically significant increase (p<0.001) in growth velocity, which is a medically relevant parameter. The safety profile was comparable to that of placebo and no drug-related serious adverse events were reported. The results from these studies will be published during 2010, starting with a presentation of the results from the first clinical study with infant formula at "The Power of Programming 2010. International conference on developmental origins of health and disease" in Munich, Germany on May 6-8, 2010.
"Kiobrina holds a great opportunity to fill a substantial medical need in neonatal care. The result from our phase II program is an important step towards a valuable product that will support preterm infants in their growth and development" said Peter Edman, CSO of Swedish Orphan Biovitrum Group.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.